The pharmaceutical giant's final major U.S. facility will rise in Pennsylvania's historic Lehigh Valley, aiming to produce its promising triple-hormone drug retatrutide and bolster domestic supply chains for blockbuster obesity treatments.
Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.
The UK's economic recovery faces a significant drag from recently implemented fiscal tightening, with growth forecasts remaining subdued for the coming year, according to a leading economic forecaster.
Glaukos Corporation secures a significant FDA nod allowing repeated administration of its sustained-release iDose TR implant, broadening treatment options for patients with glaucoma and potentially reshaping long-term care paradigms.
Amid broader market uncertainty, companies with high insider ownership and robust earnings forecasts can signal aligned interests and resilience. We examine three such UK-listed firms, from a gold miner to a convenience food giant, where those running the show have significant personal stakes.
As confidence in the Eurozone's recovery builds, investors are scrutinizing companies where executives hold significant equity stakes—a potential signal of alignment and long-term conviction. We spotlight three firms from a broader screen of 220 high-insider-ownership growth stocks.
Integral Ad Science appoints Horizon Media's Bob Lord and Amazon's former video ad chief Krishan Bhatia to its board, a move analysts say sharpens its focus on the convergence of streaming, data, and advertising technology.
Chemical and ammunition manufacturer Olin Corporation reported fourth-quarter results that missed internal forecasts, pressured by plant disruptions, supply issues, and a sharp year-end drop in chlorine demand. Executives emphasized cash preservation and cost control while navigating what they term an extended market downturn.
Novo Nordisk's newly launched oral GLP-1 drug, amycretin, has seen explosive initial demand in the U.S., potentially setting the stage for a significant financial turnaround and stock rally after a challenging previous year.
Shares of the alternative asset manager have retreated sharply from recent highs, prompting investors to question whether the stock's premium valuation remains justified. We examine the key metrics and what the pullback might signal.
Financial services firm Lazard (LAZ) reported better-than-expected fourth-quarter results, driven by record advisory fees and robust asset growth, signaling resilience in a challenging market.
From Mussolini's Rome-Berlin Axis to Bush's 'Axis of Evil,' the term has evolved into a potent geopolitical label. Its revival to describe groupings like the 'Axis of Upheaval' reveals how language frames modern conflicts and defines the boundaries of legitimacy in international politics.
Despite a modest price target reduction, Morgan Stanley reaffirms its Overweight rating on Wingstop, citing the chicken wing chain's robust unit expansion and system-wide sales momentum as key drivers for its 2026 outlook.
Aptiv PLC sees mixed but upwardly revised price targets from major analysts, with Piper Sandler upgrading the auto tech supplier to Overweight and naming it a top pick for 2026, citing its pragmatic strategy and attractive valuation.
ASML's Q4 2025 bookings, driven by AI chip demand, smashed forecasts. While management raises 2026 guidance, shareholders question the durability of the surge and the company's exposure to geopolitical headwinds.
In a move that deepens its cost leadership, Vanguard has reduced expense ratios on dozens of funds, marking the second major round of cuts under CEO Salim Ramji and highlighting the intense pressure on fees in the asset management industry.
The global packaging giant has successfully completed its court-supervised restructuring, slashing its debt burden by €1.3 billion and securing €349 million in fresh capital to stabilize operations under new ownership led by Redwood Capital Management.
The Rafah border crossing between Gaza and Egypt partially reopened Monday under European Union operation, permitting restricted passage for Palestinians after a near two-year Israeli closure. The move is part of a U.S.-brokered ceasefire agreement, though high costs and tight quotas severely limit access.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility dedicated to next-generation weight-loss drugs, signaling a long-term strategic commitment to the obesity market amid intense competition.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
